Since the clinical impact of FLT3 inhibitors is limited due to transient responses and acquired resistance [34], the STAT5 inhibitor AC-4–130 represents a solid basis for further lead structure development towards compounds with clinical value for FLT3-ITD+ AML. The gene discussed is STAT5A; the disease is acute myeloid leukemia.